Please login to the form below

Not currently logged in
Email:
Password:

Iris Pauporté joins OSE Immunotherapeutics

She becomes clinical project director at the French biotech

OSE Immunotherapeutics Iris PauportéNantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director.

Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential in other cancer indications.

She brings over 20 years of biomedical and clinical research experience to the team, and joins from the French National Cancer Institute (INCa) where she supervised the insitute's breast cancer research programme.

Prior to this, Pauporté worked for the UNICANCER hospital group as a project leader overseeing both clinical research and regulatory affairs. She also brings experience as a research coordinator at Takeda Laboratories, where she served between 1997 and 2004.

Alain Chatelin, medical director at OSE Immunotherapeutics, said: “We are very pleased to have Iris join our team.

“She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology.”

28th September 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...